U.S. markets closed
  • S&P 500

    3,845.08
    +13.69 (+0.36%)
     
  • Dow 30

    31,037.68
    +69.86 (+0.23%)
     
  • Nasdaq

    11,361.85
    +39.61 (+0.35%)
     
  • Russell 2000

    1,727.55
    -13.78 (-0.79%)
     
  • Crude Oil

    98.26
    -0.27 (-0.27%)
     
  • Gold

    1,737.60
    +1.10 (+0.06%)
     
  • Silver

    19.15
    -0.01 (-0.05%)
     
  • EUR/USD

    1.0190
    -0.0081 (-0.78%)
     
  • 10-Yr Bond

    2.9130
    +0.1040 (+3.70%)
     
  • GBP/USD

    1.1926
    -0.0026 (-0.21%)
     
  • USD/JPY

    135.8850
    +0.0430 (+0.03%)
     
  • BTC-USD

    20,480.04
    +111.59 (+0.55%)
     
  • CMC Crypto 200

    440.40
    +4.88 (+1.12%)
     
  • FTSE 100

    7,107.77
    +82.30 (+1.17%)
     
  • Nikkei 225

    26,107.65
    -315.82 (-1.20%)
     

Accuray's TomoTherapy Superior To Conventional Radiotherapy In Preserving Heart, Lung Functioning

  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

Accuray Incorporated (NASDAQ: ARAY) announced data from a Phase 3 TomoBreast trial of TomoTherapy System (TT) versus conventional post-surgery radiotherapy (CR) for breast cancer designed to test the hypothesis that TT might reduce lung-heart toxicity.

  • An analysis of patient-reported outcomes showed 10-year survival free of heart and lung deterioration was 84.5% with TomoTherapy delivered radiotherapy, a significant improvement above the 66.9% achieved with conventional radiotherapy.

  • The TomoTherapy platform, including the next-generation Radixact System, can deliver helical radiation.

  • Image-guided, intensity-modulated radiation therapy (IG-IMRT) is continuously delivered, providing greater control of the radiation dose, so it conforms precisely to the tumor and helps minimize the dose to healthy tissue and sensitive organs.

  • Previous reports of the TomoBreast trial showed that treatment with the TomoTherapy System improved the uniformity of the dose delivered to the tumor, decreased the dose to the heart and lung, and reduced heart and lung-related side effects.

  • Price Action: ARAY shares are up 2.43% at $4.01 during the market session on the last check Thursday.

See more from Benzinga

© 2022 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.